AlzChem Group AG (ACT) - Net Assets
Based on the latest financial reports, AlzChem Group AG (ACT) has net assets worth €258.23 Million EUR (≈ $301.90 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€617.68 Million ≈ $722.13 Million USD) and total liabilities (€359.45 Million ≈ $420.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AlzChem Group AG (ACT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €258.23 Million |
| % of Total Assets | 41.81% |
| Annual Growth Rate | 69.31% |
| 5-Year Change | 188.32% |
| 10-Year Change | N/A |
| Growth Volatility | 42.67 |
AlzChem Group AG - Net Assets Trend (2008–2025)
This chart illustrates how AlzChem Group AG's net assets have evolved over time, based on quarterly financial data. Also explore ACT total asset value for the complete picture of this company's asset base.
Annual Net Assets for AlzChem Group AG (2008–2025)
The table below shows the annual net assets of AlzChem Group AG from 2008 to 2025. For live valuation and market cap data, see AlzChem Group AG (ACT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €258.23 Million ≈ $301.90 Million |
+24.47% |
| 2024-12-31 | €207.47 Million ≈ $242.56 Million |
+26.85% |
| 2023-12-31 | €163.56 Million ≈ $191.22 Million |
+12.07% |
| 2022-12-31 | €145.95 Million ≈ $170.63 Million |
+62.95% |
| 2021-12-31 | €89.56 Million ≈ $104.71 Million |
+30.45% |
| 2020-12-31 | €68.66 Million ≈ $80.27 Million |
+11.91% |
| 2019-12-31 | €61.35 Million ≈ $71.72 Million |
-10.30% |
| 2018-12-31 | €68.39 Million ≈ $79.96 Million |
+18.13% |
| 2017-12-31 | €57.89 Million ≈ $67.68 Million |
-- |
| 2016-12-31 | €0.00 ≈ $0.00 |
-- |
| 2015-12-31 | €0.00 ≈ $0.00 |
-- |
| 2014-12-31 | €0.00 ≈ $0.00 |
-- |
| 2013-12-31 | €1.94K ≈ $2.27K |
-78.14% |
| 2012-12-31 | €8.86K ≈ $10.36K |
-29.71% |
| 2011-12-31 | €12.61K ≈ $14.74K |
-26.85% |
| 2010-12-31 | €17.24K ≈ $20.16K |
-38.84% |
| 2009-12-31 | €28.19K ≈ $32.96K |
-15.78% |
| 2008-12-31 | €33.48K ≈ $39.14K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AlzChem Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27386247326.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €232.11 Million | 90.56% |
| Common Stock | €101.76 Million | 39.71% |
| Other Comprehensive Income | €-12.40 Million | -4.84% |
| Total Equity | €256.30 Million | 100.00% |
AlzChem Group AG Competitors by Market Cap
The table below lists competitors of AlzChem Group AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhuhai Orbita Control Eng
SHE:300053
|
$1.83 Billion |
|
AOZORA BANK LTD ADR/20
F:AON0
|
$1.83 Billion |
|
Rogers Corporation
NYSE:ROG
|
$1.83 Billion |
|
Lao Feng Xiang Co Ltd A
SHG:600612
|
$1.83 Billion |
|
Redington Limited
NSE:REDINGTON
|
$1.83 Billion |
|
Shandong Sacred Sun Power Sources Co Ltd
SHE:002580
|
$1.83 Billion |
|
Dongguan Eontec Co Ltd
SHE:300328
|
$1.82 Billion |
|
Silicon2 Co. Ltd.
KQ:257720
|
$1.82 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AlzChem Group AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 205,537,000 to 256,297,000, a change of 50,760,000 (24.7%).
- Net income of 63,459,000 contributed positively to equity growth.
- Dividend payments of 18,190,000 reduced retained earnings.
- Share repurchases of 4,520,000 reduced equity.
- New share issuances of 3,019,000 increased equity.
- Other comprehensive income increased equity by 69,160,000.
- Other factors decreased equity by 62,168,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €63.46 Million | +24.76% |
| Dividends Paid | €18.19 Million | -7.1% |
| Share Repurchases | €4.52 Million | -1.76% |
| Share Issuances | €3.02 Million | +1.18% |
| Other Comprehensive Income | €69.16 Million | +26.98% |
| Other Changes | €-62.17 Million | -24.26% |
| Total Change | €- | 24.70% |
Book Value vs Market Value Analysis
This analysis compares AlzChem Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 50433.30x to 6.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | €0.00 | €165.90 | x |
| 2009-12-31 | €0.00 | €165.90 | x |
| 2010-12-31 | €0.00 | €165.90 | x |
| 2011-12-31 | €0.00 | €165.90 | x |
| 2012-12-31 | €0.00 | €165.90 | x |
| 2013-12-31 | €0.00 | €165.90 | x |
| 2014-12-31 | €-4.08 | €165.90 | x |
| 2015-12-31 | €-4.08 | €165.90 | x |
| 2016-12-31 | €-0.01 | €165.90 | x |
| 2017-12-31 | €5.47 | €165.90 | x |
| 2018-12-31 | €6.58 | €165.90 | x |
| 2019-12-31 | €5.87 | €165.90 | x |
| 2020-12-31 | €6.57 | €165.90 | x |
| 2021-12-31 | €8.61 | €165.90 | x |
| 2022-12-31 | €14.15 | €165.90 | x |
| 2023-12-31 | €15.89 | €165.90 | x |
| 2024-12-31 | €20.20 | €165.90 | x |
| 2025-12-31 | €25.36 | €165.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AlzChem Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.29%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 2.41x
- Recent ROE (24.76%) is above the historical average (-8.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -14.39% | 0.00% | 0.00x | 1.97x | €-8.16K |
| 2009 | -18.74% | 0.00% | 0.00x | 2.33x | €-8.10K |
| 2010 | -63.50% | 0.00% | 0.00x | 3.21x | €-12.67K |
| 2011 | -36.71% | 0.00% | 0.00x | 1.38x | €-5.89K |
| 2012 | -42.27% | 0.00% | 20367.40x | 1.59x | €-4.63K |
| 2013 | -228.45% | 0.00% | 22091.00x | 7.05x | €-4.62K |
| 2014 | 0.00% | 0.00% | 11827.87x | 0.00x | €4.14 Million |
| 2015 | 0.00% | -0.01% | 8897.62x | 0.00x | €4.12 Million |
| 2016 | 0.00% | -0.01% | 5081.38x | 0.00x | €-23.65K |
| 2017 | 36.63% | 5.76% | 1.26x | 5.03x | €14.83 Million |
| 2018 | 33.81% | 6.03% | 1.20x | 4.68x | €15.95 Million |
| 2019 | 30.08% | 4.78% | 1.10x | 5.73x | €12.00 Million |
| 2020 | 29.44% | 5.19% | 1.07x | 5.30x | €13.00 Million |
| 2021 | 31.49% | 6.53% | 1.12x | 4.31x | €18.83 Million |
| 2022 | 20.87% | 5.54% | 1.28x | 2.94x | €15.65 Million |
| 2023 | 21.42% | 6.40% | 1.27x | 2.63x | €18.46 Million |
| 2024 | 26.31% | 9.76% | 1.15x | 2.35x | €33.52 Million |
| 2025 | 24.76% | 11.29% | 0.91x | 2.41x | €37.83 Million |
Industry Comparison
This section compares AlzChem Group AG's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $3,369,987,952
- Average return on equity (ROE) among peers: -34.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AlzChem Group AG (ACT) | €258.23 Million | -14.39% | 1.39x | $1.83 Billion |
| GRAPHENE MANUFACT.GROUP (0GF) | $8.54 Million | -86.66% | 0.78x | $152.93 Million |
| Orion Engineered Carbons SA (0OE) | $474.90 Million | 9.31% | 2.91x | $318.41 Million |
| H&R GmbH & Co. KGaA (2HRA) | $471.16 Million | 9.06% | 1.04x | $183.88 Million |
| Dotz Nano Ltd (57N) | $421.99K | -248.22% | 1.80x | $3.81 Million |
| EXPLOS. PROD. CHIM.EO 31 (9Z50) | $144.93 Million | 14.73% | 2.07x | $536.15 Million |
| Altech Chemicals Ltd (A3Y) | $88.93 Million | 2.62% | 0.01x | $27.76 Million |
| AIR LIQUIDE ADR 1/5/EO 11 (AILA) | $24.57 Billion | 11.23% | 1.02x | $103.86 Billion |
| AKZO NOBEL SPONS.ADRS 1/3 (AKUP) | $4.55 Billion | 9.72% | 2.20x | $8.57 Billion |
| BRAIN Biotech AG (BNN) | $23.01 Million | -35.97% | 2.08x | $51.56 Million |
About AlzChem Group AG
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, f… Read more